J&J's Imaavy demonstrates long-term disease control in myasthenia gravis
Summary
J&J’s Imaavy (nipocalimab) shows sustained gMG improvements through 120 weeks, cutting IgG by 64% and boosting symptom control. Read more here.
Description
J&J’s Imaavy (nipocalimab) shows sustained gMG improvements through 120 weeks, cutting IgG by 64% and boosting symptom control. Read more here.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source